NDA 019891 · Rhodes Pharms
Dilaudid
Hydromorphone Hydrochloride · Oral
Last checked: Nov 20, 2026Latest source record: Jun 18, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1992
Dec 7, 1992
Approved uses
1
Original approval plus efficacy supplements
Registered trials
290
61 Phase 3, 22 recruiting
FAERS reports
91,827
85,087 serious, 28,204 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: SERIOUS AND LIFE-THREATENING RISKS FROM USE OF HYDROMORPHONE HYDROCHLORIDE WARNING: SERIOUS AND LIFE-THREATENING RISKS FROM USE OF HYDROMORPHONE HYDROCHLORIDE See full prescribing information for complete boxed warning . Ensure accuracy when prescribing, dispensing, and administering hydromorphone hydrochloride oral solution. Dosing errors due to confusion between mg and mL can result in accidental overdose and death. ( 2.1 , 5.1 ) Hydromorphone hydrochloride oral solution or hydromorphone hydrochloride tablets expose users to risks of addiction, abuse, and misuse, which can lead to overdose and death. Assess patient's risk before prescribing and reassess regularly for these behaviors and conditions. ( 5.2 ) Serious, life-threatening, or fatal respiratory depression may occur, especially upon initiation or following a dosage increase. To reduce the risk of respiratory...
What it is approved for
From the label in effect May 14, 2026.
Hydromorphone hydrochloride oral solution and hydromorphone hydrochloride tablets are indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. Hydromorphone hydrochloride oral solution and hydromorphone hydrochloride tablets contain hydromorphone, an opioid agonist, and are indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. ( 1 ) Limitations of Use Because of the risks of addiction, abuse, misuse, overdose, and death, which can occur at any dosage or duration and persist over the course of therapy, reserve opioid analgesics, including hydromorphone hydrochloride oral solution or hydromorphone hydrochloride tablets, for use in patients for whom alternative treatment options are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain. ( 1 , 5.2 ) Limitations of Use Because of the risks of addiction, abuse, misuse, overdose, and death, which can occur at any dosage or duration and persist over the course of therapy [see Warnings and Precautions (5.2) ] , reserve opioid analgesics, including hydromorphone hydrochloride oral solution and hydromorphone hydrochloride tablets for use in patients for whom alternative treatment options are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain.
Mechanism: Hydromorphone is a full opioid agonist and is relatively selective for the mu-opioid receptor, although it can bind to other opioid receptors at higher doses. The principal therapeutic action of hydromorphone is analgesia. Like all full opioid agonists, there is no ceiling effect for analgesia with morphine. Clinically, dosage is titrated to provide adequate analgesia and may be limited by adverse reactions, including respiratory and CNS depression. The precise mechanism of the analgesic action is unknown. However, specific CNS opioid receptors for endogenous compounds with opioid-like...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Dec 7, 1992 Original approval · Type 3 - New Dosage Form REMS
1 products under this application
- DILAUDID · HYDROMORPHONE HYDROCHLORIDE 5MG/5ML · SOLUTION, ORAL · Prescription · TE AA
Clinical trials
Interventional ClinicalTrials.gov studies with "Hydromorphone" as an intervention, any sponsor and status, largest first.
Vanderbilt UniversityAcademic, hospital or other
NCT02625181 · 27,034 participants · Start Jul 2016 · Primary completion Nov 2, 2017
Drug: Propofol; Sevoflurane and 28 more · For: Postoperative Nausea and Vomiting
Sites: Nashville, Tennessee
- Patient-controlled Intravenous Analgesia Combined With Different Opioid Receptors for Gastrointestinal SurgeryPivotal-lookingCompleted
Xijing HospitalAcademic, hospital or other
NCT05576675 · 4,342 participants · Start May 1, 2018 · Primary completion Mar 31, 2022
Drug: sufentanil + nalbuphine; Sufentanil and 1 more · For: Gastrointestinal Surgery
Sites: XIan, China
- Recommendations of Enhanced Recovery Interventions for Patient's Clinical Team and Collection of Associated DataPivotal-lookingCompleted
Jennifer Holder-MurrayAcademic, hospital or other
NCT04606264 · 3,395 participants · Start May 15, 2023 · Primary completion Mar 21, 2025
Drug: Neuraxial Analgesia; Regional Block 1: Paravertebral and 6 more · For: Perioperative Optimization
Sites: Pittsburgh, Pennsylvania · 3 sites in all
- MAST Trial: Multi-modal Analgesic Strategies in TraumaPivotal-lookingCompleted
The University of Texas Health Science Center, HoustonAcademic, hospital or other
NCT03472469 · 1,561 participants · Start Apr 2, 2018 · Primary completion Jul 3, 2019
Drug: Acetaminophen IV/PO; Acetaminophen PO and 9 more · For: Nonspecific Pain Post Traumatic Injury
Sites: Houston, Texas
- Determining the Effect of an "Alternate Recovery Protocol" Versus Current Standard of Care After Cesarean SectionPivotal-lookingTerminated
Brest, Norman A., M.D.Academic, hospital or other
NCT03330119 · 1,494 participants · Start Oct 4, 2017 · Primary completion Jun 20, 2018
Drug: Alternate Management; Control · For: Pregnancy Related; Narcotic Use
Sites: Wynnewood, Pennsylvania
- IV PCA With or Without Continuous Dose vs Oral Opioid to Maintain Analgesia for Severe Cancer Pain After Successful TitrationPivotal-lookingCompleted
Fujian Cancer HospitalGovernment (non-federal)
NCT04785768 · 1,372 participants · Start Jul 1, 2021 · Primary completion May 1, 2024
Drug: Hydromorphone Hydrochloride Injection; Hydromorphone Hydrochloride Injection and 1 more · For: Cancer Pain
Sites: Fuzhou, China
- Effect of Tramadol in Prevention of Postpartum DepressionPivotal-lookingCompleted
Xinqiao Hospital of ChongqingAcademic, hospital or other
NCT03309163 · 1,230 participants · Start Oct 9, 2017 · Primary completion Jun 13, 2019
Drug: Tramadol; Hydromorphone and 1 more · For: Caesarean Section
Sites: Chongqing, China
- Intravenous Remifentanil for Labor AnalgesiaPivotal-lookingCompleted
Nanjing Medical UniversityAcademic, hospital or other
NCT00710086 · 1,000 participants · Start Jul 2008 · Primary completion Sep 2009
Drug: Hydromorphone; Remifentanil · For: Labor Pain
Sites: Nanjing, China
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug dependence35,119
- overdose23,079
- pain22,354
- emotional distress17,705
- death14,926
- drug withdrawal syndrome14,329
- toxicity to various agents10,084
- nausea4,811
- drug ineffective4,543
- fatigue3,652
- vomiting3,601
- off label use3,489
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 287 |
| 2005 | 320 |
| 2006 | 383 |
| 2007 | 437 |
| 2008 | 438 |
| 2009 | 647 |
| 2010 | 866 |
| 2011 | 980 |
| 2012 | 1,400 |
| 2013 | 1,246 |
| 2014 | 1,380 |
| 2015 | 1,964 |
| 2016 | 2,588 |
| 2017 | 3,922 |
| 2018 | 23,055 |
| 2019 | 2,735 |
| 2020 | 8,703 |
| 2021 | 17,398 |
| 2022 | 15,695 |
| 2023 | 2,349 |
| 2024 | 2,204 |
| 2025 | 1,754 |
| 2026 | 1,074 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Dilaudid (Hydromorphone HCl)
2024 spending
$350K
Beneficiaries
253
757 claims
Per beneficiary
$1,384
$4.18 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $1,667,512 |
| 2021 | $1,420,060 |
| 2022 | $1,121,656 |
| 2023 | $905,514 |
| 2024 | $350,270 |
Part B: Dilaudid* (Hydromorphone HCL/PF*) · HCPCS J1171
2024 spending
$99K
Beneficiaries
932
2,056 claims
Per beneficiary
$106
2024 ASP limit $0.09 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $0 |
| 2023 | $0 |
| 2024 | $98,543 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- 2025 guideline update to acute treatment of migraine for adults in the emergency department: The American Headache Society evidence assessment of parenteral pharmacotherapies.
Robblee J, Minen MT, Friedman BW, et al. · Headache 2026 · Systematic Review, Meta-Analysis
- Effect of Intraoperative Esketamine Infusion on Postoperative Sleep Disturbance After Gynecological Laparoscopy: A Randomized Clinical Trial.
Qiu D, Wang XM, Yang JJ, et al. · JAMA Netw Open 2022 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Opioids for cancer pain - an overview of Cochrane reviews.
Wiffen PJ, Wee B, Derry S, et al. · Cochrane Database Syst Rev 2017 · Research Support, Non-U.S. Gov't, Systematic Review
- Investigational Drugs for the Treatment of Postherpetic Neuralgia: Systematic Review of Randomized Controlled Trials.
Huerta MÁ, Garcia MM, García-Parra B, et al. · Int J Mol Sci 2023 · Systematic Review
- Effectiveness and Safety of Hydromorphone Compared to Morphine for Postoperative Analgesia: A Systematic Review and Meta-analysis.
Li Y, Yue X, Liang S, et al. · Pain Physician 2024 · Systematic Review, Meta-Analysis
- Hydromorphone for cancer pain.
Li Y, Ma J, Lu G, et al. · Cochrane Database Syst Rev 2021 · Meta-Analysis, Research Support, Non-U.S. Gov't
Sponsor: Rhodes Pharms
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.